New randomized controlled trial on RevitalVision
Effects of Perceptual Learning on Deprivation Amblyopia in Children with Limbal Dermoid: A Randomized Controlled Trial.
The study compared 2 groups of children with amblyopia after corneal transplant : One group received standard patching therapy and the second group received patching + RevitalVision.
The group that underwent RevitalVision therapy experienced statistically significant improvement in vision.Read the full study
RevitalVision at HIMSS 22
This year, the Israel Export Institute together with the Foreign Trade Administration – Ministry of Economy & Industry will present 18Israeli Digital Health companies. And we are proud to be amongst these innovative companieschrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fwww.export.gov.il%2Fapi%2FMedia%2FDefault%2FFiles%2FExhibitions%2Fexhibitions_HIMSS22_catalogue.pdf&clen=2004600&chunk=true
RevitalVision will present at the AAPOS 2022 – Arizona
2022 Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), on March 23-27, 2022.
RevitalVision on The Ophthalmologist
Yair Yahav, CEO and founder of RevitalVision, was interviewed in The Ophthalmologist about how we improve vision in adult amblyopia and other eye diseases and vision impairments
12-15 November 2021
AAO annual meeting
Come meet our experts at the AAO annual meeting, taking place in New Orleans this November
3-6 November 2021
American Academy of Optometry Annual Meeting
We’re excited to be one of the exhibitors at the American Academy of Optometry Annual Meeting – which will be taking place in Boston
Visit us in the exhibit hall at booth #843
RevitalVision received reimbursement code in the USA
RevitalVision is a standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical Association (AMA).
A New Adult Amblyopia study presented at AIOS 2020 (All India Ophthalmology Society)
meeting 2020 confirming again the efficacy of RevitalVision in improving vision in adult amblyopiaDownload ppt
REVITALVISION will participate at the upcoming AAOPT (AMERICAN ACADEMY of OOPTOMETRY)
Meeting in Nashville, TN, USA 7-10 OctoberLink to article
21-24 April 2021
REVITALVISION will participate at the upcoming 41st ESA (EUROPEAN STRABISMOLOGICAL ASSOCIATION)
Meeting in PARIS 21th /24th April 2021Link to article
Tel Aviv Medical Center is recruiting Age related Macular Degeneration patients for a REVITALVISION clinical study
A Proof-of-Concept, Prospective, Open label, Randomized Clinical Study Evaluating RevitalVision® Therapy for Improving Best Corrected Visual Acuity (BCVA) and Contrast Sensitivity Function (CSF) in Patients Suffering from stabler Age related Macular Degeneration (AMD)